🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

InflaRx hires new VP and Head of Investor Relations

EditorIsmeta Mujdragic
Published 02/22/2024, 07:45 AM
© Reuters.

JENA, Germany - InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company, has announced the appointment of Jan Medina, CFA, as the new Vice President and Head of Investor Relations. With over two decades of experience in the life sciences sector, Medina is poised to strengthen the company's investor relations and support its clinical programs.

Medina's extensive background includes expertise in investor relations, communications, and equity research. Prior to joining InflaRx, he served as Vice President at Olink Proteomics, focusing on Investor Relations & Capital Markets. His career has spanned roles in consultancy firms and companies specializing in oncology, hematology, and medical technology, alongside positions at global investment banks and boutique research firms.

InflaRx's CEO, Prof. Niels C. Riedemann, expressed confidence in Medina's abilities, citing his proven track record and deep capital markets network as invaluable assets for the company's future endeavors.

Medina shared his enthusiasm for his role at InflaRx, particularly noting the potential of the company's new oral C5aR inhibitor, INF904, and the progress of vilobelimab, which is currently in Phase III trials for pyoderma gangrenosum, a condition lacking approved treatments in the U.S. and Europe.

InflaRx specializes in anti-inflammatory therapeutics targeting the complement system, with a focus on the inflammatory mediator C5a. Its lead product candidate, vilobelimab, is a first-in-class anti-C5a monoclonal antibody that has shown promise in clinical trials for various inflammatory diseases.

The company, founded in 2007, operates from Germany and the United States, with subsidiaries InflaRx GmbH and InflaRx Pharmaceuticals Inc. being part of the InflaRx group.

This news is based on a press release statement and does not include any forward-looking statements.

InvestingPro Insights

InflaRx N.V. (NASDAQ:IFRX) has recently bolstered its investor relations team with the appointment of Jan Medina, CFA, as the new Vice President and Head of Investor Relations. As InflaRx continues to advance its clinical programs, particularly with its lead product candidate vilobelimab, it is worth noting the company's financial health and market performance through key metrics from InvestingPro.

InvestingPro Data indicates that InflaRx holds a market capitalization of 88.91 million USD, which is relatively modest within the biopharmaceutical industry. The company's Price / Book ratio as of the last twelve months ending Q3 2023 stands at 0.7, which could suggest that the stock is potentially undervalued relative to its assets. Moreover, the stock has experienced a significant pullback, with a 6 Month Price Total Return of -58.74%, which may attract investors looking for a potential rebound opportunity.

Among the InvestingPro Tips for InflaRx, two stand out as particularly relevant to investors considering the company's future prospects. First, despite holding more cash than debt, the company is rapidly burning through cash, which could impact its ability to fund ongoing and future clinical trials. Second, analysts do not anticipate InflaRx to be profitable this year, reflecting the inherent risks and long-term investment horizon typically associated with clinical-stage biopharmaceutical companies.

For investors seeking a deeper dive into InflaRx's financials and market prospects, InvestingPro offers additional insights. There are 9 more InvestingPro Tips available, which can be accessed through the company-specific InvestingPro page at https://www.investing.com/pro/IFRX. To enrich your investment research, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, providing a more comprehensive analysis to inform your investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.